Virtus Biotech Clinical Trials ETF
4 hedge funds and large institutions have $7.75M invested in Virtus Biotech Clinical Trials ETF in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.16M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$1.14M |
| 3 |
Jane Street
New York
|
+$350K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$822 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $6.23M | +$6.16M | +224,754 | New |
|
|
VKH
2
Virtu KCG Holdings
New York
| $1.16M | +$1.14M | +41,727 | New |
|
|
3
Jane Street
New York
| $354K | +$350K | +12,758 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $1K | +$822 | +30 | New |
|
BBC Hedge Fund Activity: Q4 2014 in Review
4 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2014, worth a combined $7.75M.
Buyers outnumbered sellers: 4 funds opened new BBC positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $6.16M.
- 4 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $7.75M of Virtus Biotech Clinical Trials ETF stock for Q4 2014.
- 4 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2014 and 0 closed out, a net change of +4 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2014 was Deutsche Bank, an estimated $6.16M added.
Based on aggregated 13F filings for Q4 2014.